TG Therapeutics Secures $500M to Advance BRIUMVI in Relapsing Multiple Sclerosis
TG Therapeutics secured $500 million in non-dilutive capital through a new credit facility, supporting the expansion of BRIUMVI, a glycoengineered anti-CD20 monoclonal antibody for relapsing multiple sclerosis. Designed for efficient B-cell depletion at low doses, BRIUMVI underpins the company’s growth strategy, alongside ongoing investment in pipeline development.
TG Therapeutics announced that it has entered into a new five-year, $750 million senior secured credit facility with funds managed by Blue Owl Capital, reinforcing its financial capacity to support commercial and pipeline expansion. The agreement replaces the company’s existing $250 million facility, resulting in a net inflow of $500 million in non-dilutive capital, with an option to access up to $1 billion in total financing, subject to mutual agreement.
The financing comes as TG Therapeutics continues to scale its commercial operations, particularly around BRIUMVI (ublituximab-xiiy), a glycoengineered anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis. By targeting a distinct epitope on CD20-expressing B cells, BRIUMVI enables efficient B-cell depletion at lower doses, reflecting advances in antibody engineering aimed at improving therapeutic precision and tolerability.
Commenting on the transaction, Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, ““We are pleased to announce this expanded credit facility with funds managed by Blue Owl, which significantly enhances our financial position with increased scale and improved terms compared to our prior facility. This financing builds on our cash flow positive business and provides substantial non-dilutive capital to support opportunistic share repurchases and business development, while continuing to invest in the growth of BRIUMVI and advancement of our pipeline. The expansion of our share repurchase program underscores our confidence in our business and our commitment to delivering long-term shareholder value. We appreciate Blue Owl’s continued relationship and support.”
In parallel with the new facility, the company’s Board of Directors has expanded its share repurchase program from $100 million to $300 million. As of March 18, 2026, approximately $38 million of shares had already been repurchased at an average price of $28.98 per share, signaling a proactive capital allocation strategy.
ABOUT BRIUMVI® (ublituximab-xiiy)
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.
Comments
No Comments Yet!